NCT04199689: Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)
- State
- Under way
- Phase
- Phase 3
- People
- 6,033 taking part
- Started
- 27 Feb 2020
- Primary completion
- 15 Jan 2027
- Arms
- 9vHPV vaccine
- Results
- None posted
- 16 Dec 2019: Trial registered
- 27 Feb 2020: Trial started